Nucleic acid extraction remains a major infrastructure barrier to decentralised molecular influenza testing because bead-based purification is typically performed with mains-powered extractors operated by trained personnel. This study evaluated whether a manual, centrifugation-free magnetic bead extraction format, SmartLid, could match or exceed the performance of a standard automated magnetic-bead extractor for downstream influenza RT-qPCR sensitivity and subtyping success.
The primary objective was to compare extraction efficiency and subtyping performance between SmartLid and an automated extractor (Nextractor NX-48S) using clinical nasopharyngeal specimens from a National Influenza Centre during the 2024–2025 season.
A total of 311 nasopharyngeal specimens collected during the 2024–2025 influenza season were tested in paired fashion: each specimen yielded two eluates, one processed with SmartLid and one processed with the automated extractor. The paired design allowed direct comparison of extraction outcomes and downstream amplification for identical samples.
All paired eluates were subjected to identical monoplex RT-qPCR assays targeting influenza A(H1N1)pdm09, A(H3), and B/Victoria subtypes.
SmartLid is described as a centrifugation-free manual format in which a removable magnetic key shuttles paramagnetic beads through pre-aliquoted lysis/binding, wash, and elution buffers without pipetting or powered instrumentation. The comparator was an automated magnetic-bead extractor, the Nextractor NX-48S, representing a typical laboratory reference workflow.
Both methods produced eluates for RT-qPCR under identical amplification conditions so that differences reflect extraction efficiency rather than downstream assay variation.
Monoplex RT-qPCR assays were run for influenza A(H1N1)pdm09, A(H3), and B/Victoria. Paired testing permitted assessment of analytical sensitivity (measured as cycle threshold, Ct) and practical outcomes relevant to clinical subtyping.
Both extraction workflows showed 100% specificity in this dataset: 47 of 47 negative specimens were negative by both methods, with no false positives reported.
Subtyping success differed between methods. Among 264 reference-positive specimens, SmartLid-extracted eluates allowed successful subtype identification in 263/264 specimens (99.62%), whereas the automated extractor achieved subtyping in 241/264 specimens (91.29%). The absolute difference in subtyping success was 8.33 percentage points. The number of discordant paired results strongly favored SmartLid: 23 pairs were positive after SmartLid but negative after automated extraction, while only 1 pair showed the opposite discordance. The authors report McNemar P < 0.001 for these discordances.
Among 240 complete paired comparisons available for Ct analysis, Ct values were lower following SmartLid extraction. The median paired Ct difference was −2.78 cycles. An estimated location shift was −2.60 cycles with a 95% confidence interval of −2.82 to −2.37; P < 0.001. Lower Ct values indicate higher nucleic acid yield or improved assay sensitivity after SmartLid extraction.
Rank-ordering of specimens by signal intensity was preserved between methods, with a Spearman correlation (rho) of 0.84, indicating consistent relative specimen viral loads despite absolute shifts in Ct.
The Ct advantage with SmartLid was observed across all three tested subtypes (A(H1N1)pdm09, A(H3), and B/Victoria) and was present in both fresh and frozen specimens. The authors report the advantage remained statistically significant after adjustment (adjusted P < 0.001).
Specimens that were detectable only after SmartLid extraction had higher Ct values than specimens detected by both methods. Median Ct for SmartLid-only detections was 34.37 compared with 28.54 for dual-detected specimens (P < 0.001). This pattern locates the observed performance gain near the assay detection limit.
The data indicate SmartLid provides improved extraction efficiency that translates into lower Ct values and higher subtyping success, particularly for specimens with low target concentration close to the assay limit of detection. The majority of discordant detections occurred in the high-Ct range, consistent with incremental increases in nucleic acid recovery being sufficient to convert previously undetected samples into detectable ones.
The study received ethical approval from the Ethics Committee of the East Health Area of Valladolid (Spain) under code PI-23-3208 in 2023 and adhered to the Declaration of Helsinki. The authors state that all necessary patient consent and institutional approvals were obtained. Data produced in the study are available on reasonable request to the authors.
Competing interests were declared: several authors have financial interest in ProtonDx Ltd, which holds an exclusive license to intellectual property linked to SmartLid technology and associated trademarks. Other author disclosures and funding sources were provided in the source report.
Within this clinical specimen set, an instrument-free manual magnetic-bead extraction format (SmartLid) exceeded the extraction efficiency of an automated reference workflow, producing lower Ct values and higher influenza subtyping success. The gain was most evident near the assay detection limit, suggesting SmartLid may enable more reliable detection and subtyping of low-viral-load specimens.
These findings suggest the potential for extending quality-assured influenza subtyping beyond centralized laboratory settings by using an instrument-free extraction method, though practical implementation, scalability, and independent validation would be required. The source article provides the full dataset on request and notes the declared competing interests linked to the technology.